Results 81 to 90 of about 10,088 (191)

RIFAXIMIN COMPOSITIONS AND METHOD OF USE

open access: yes, 2008
Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin gamma are described, along with the production of medicinal preparations containing rifaximin for oral and topical ...
CAMPANA M.   +6 more
core   +1 more source

Frequent high-level rifaximin resistance in Escherichia coli associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study

open access: yesMicrobiology Spectrum
We conducted a prospective, controlled study to assess the prevalence of high-level rifaximin resistance in intestinal Escherichia coli (E. coli) among patients with liver cirrhosis (LC).
L. Boll   +8 more
doaj   +1 more source

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome

open access: yes, 2015
Natalya Iorio, Zubair Malik, Ron Schey Section of Gastroenterology, Department of Medicine, Temple University Hospital, Philadelphia, PA, USA Abstract: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by ...
Schey R, Iorio N, Malik Z
core  

Comparison of network topology before and after rifaximin.

open access: yes, 2013
Intersection indicates the nodes and network common to both before and after rifaximin. The table shows that the majority of nodes involved were common (intersection) between the groups while the network density (average number of neighbors and network ...
Phillip B. Hylemon (253333)   +15 more
core   +1 more source

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy

open access: yes, 2018
Zhida Wang,1 Pei Chu,2 Wenjin Wang2 1Comprehensive Clinical Skill Training Center, The First Hospital of Lanzhou University, Lanzhou 730030, China; 2Department of Emergency, The First Hospital of Lanzhou University, Lanzhou 730030, China Background ...
Chu P, Wang W, Wang Z
core  

Structural elucidation of the Rifaximin Ph. Eur. Impurity H

open access: yes, 2010
Rifaximin, a semisynthetic, rifamycin-based non-systemic antibiotic is used in the treatment of acute and chronic gastrointestinal disorders. The aim of this study was the elucidation of the molecular structure of the 802 Dalton impurity which was found ...
R. Stradi   +9 more
core   +1 more source

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

open access: yes, 2015
Sara Soldi,1 Sotirios Vasileiadis,2 Francesca Uggeri,1 Mariachiara Campanale,3 Lorenzo Morelli,4 Maria Vittoria Fogli,5 Fiorella Calanni,5 Maria Grimaldi,5 Antonio Gasbarrini31AAT – Advanced Analytical Technologies Srl, Piacenza, Italy; 2Centre for
Uggeri F   +8 more
core  

The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a “real-life” study [PDF]

open access: yes, 2017
Introduction: Symptomatic uncomplicated diverticular disease of the colon (SUDD) is one of the most common diseases with which patients present to a gastroenterologist. Mild forms of diverticulitis can also be treated using rifaximin. Although numerous
Grażyna Rydzewska, Andrzej Moniuszko
core   +1 more source

Synthesis rifaximin with copper (Rif-Cu) and copper oxide (Rif-CuO) nanoparticles Considerable dye decolorization: An application of aerobic oxidation of eco-friendly sustainable approach

open access: yesHeliyon
In this study, rifaximin with copper (Cu) and copper oxide (CuO) nanoparticles (NPs) were synthesised. The resultant CuO nanoparticles were used to degrade Rhodamine B (RhB) and Coomassie Brilliant Blue (G250).
Janani Mullaivendhan   +3 more
doaj   +1 more source

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy

open access: yesTherapeutic Advances in Gastroenterology, 2019
Background: After 5  years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-α treatment in a real-world ...
Rosalie C. Oey   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy